THC/CBD complete analysis

Medical cannabis products require precise cannabinoid quantification for therapeutic efficacy, regulatory compliance, and patient safety - THC and CBD ratios determine pharmacological effects while regulatory limits prevent psychoactive exposure. Comprehensive cannabinoid profiling following Swissmedic requirements quantifies THC, CBD, and related compounds in medical cannabis products through GC-MS analysis distinguishing between psychoactive and therapeutic cannabinoids. This analysis ensures products meet regulatory limits with THC quantification confirming levels remain below psychoactive thresholds for CBD products, CBD quantification validating therapeutic content matching labeled claims, and related cannabinoid profiling providing complete chemical characterization. Critical for medical cannabis quality control ensuring batch-to-batch consistency in cannabinoid content, validating THC levels remain below legal limits in CBD products preventing psychoactive effects, and supporting product registration for cannabis-based medicines requiring comprehensive cannabinoid characterization. The GC-MS methodology provides definitive cannabinoid identification through mass spectral confirmation, quantifies major cannabinoids including THC, CBD, CBN, and CBG providing complete profiles, and detects degradation products indicating improper storage or aging. For pharmaceutical cannabis applications, cannabinoid profiling validates extraction processes achieve target cannabinoid ratios, demonstrates stability throughout shelf life maintaining therapeutic potency, and supports dosing claims ensuring patients receive consistent cannabinoid exposure. Swiss medical cannabis regulations require documented cannabinoid testing for product authorization with ongoing batch release testing maintaining compliance, while international markets increasingly demand similar data for medical cannabis product approval.

No.
100706
Method
GC-MS for cannabinoid profile
Standard
Stage category
Industry category
Analyses category
Sample type
Finished device, Bulk material
Sample requirement (type)
Sterile or non sterile
Sample quantities
1 gram
Lead Time Standard (Days)
10
Lead Time Express (Days)
5
Lead Time Super Express (Days)
unavailable
Test facility
In House
GLP
No
Add this test to cart to request an offer.

Do you need some help?

Other similar tests

ISO 10993-18, EPA 8260, EPA 8270
Chemistry - PFAS analysis

Persistent environmental contaminants accumulate in ecosystems and human bodies creating long-term health concerns - PFAS compounds resist degradation while bioaccumulating, making their presence in medical devices increasingly problematic under evolving regulations. PFAS (per- and polyfluoroalkyl substances) analysis by LC-MS/MS addresses these persistent environmental contaminants of increasing regulatory concern, with methodology targeting expanding lists of restricted PFAS compounds. The analytical approach achieves sub-ppb detection limits required for compliance with stringent regulations limiting these "forever chemicals" that persist in environment and bioaccumulate in organizms. Critical for devices with fluoropolymer components including PTFE tubing and coatings, demonstrating compliance with emerging PFAS regulations restricting these persistent compounds, and addressing stakeholder concerns about environmental persistence even when health effects remain uncertain. For medical devices, PFAS testing validates that fluoropolymer processing adequately removes manufacturing residues including perfluorooctanoic acid (PFOA) used in PTFE production, alternative materials replacing restricted PFAS don't introduce equally problematic fluorinated compounds, and device use doesn't release PFAS at levels triggering regulatory concerns. The LC-MS/MS methodology provides sensitive detection distinguishing individual PFAS compounds in complex mixtures, quantifies both legacy PFAS like PFOS and PFOA plus replacement compounds, and accommodates regulatory method updates as restricted compound lists expand. Manufacturing validation ensures processing removes PFAS contamination from equipment and materials, incoming material screening verifies supplier claims about PFAS-free status, and product testing demonstrates compliance with market-specific regulations varying by region. The analysis proves essential as regulations tighten globally with EU restrictions expanding, US EPA limits strengthening, and environmental advocacy increasing pressure for PFAS elimination from consumer and medical products.